EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)

Ryan P Coyle iD, Mary Morrow, Sarah C Mann, Vincent Mainella, Samuel L Ellis, Stefanie Schwab, Corwin Coppinger, Nicholas Barker, Lucas Ellison, Jia-Hua Zheng, Subhi Al Zuabi, Pamela E Alpert und 9 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae212 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Ryan P Coyle und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora,…. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Dried Blood Spot Testing, Emtricitabine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide/emtricitabine (TAF/FTC)–based antiretroviral therapy (ART).

Methods

For 16 weeks, PWH received TAF/FTC-based ART co-encapsulated with an ingestible sensor to directly measure cumulative (enrollment to final visit) and 10-day adherence. At monthly visits, intraerythrocytic concentrations of TFV-DP and FTC-TP in DBS were quantified and summarized at steady-state (week 12 or 16) as median (interquartile range). Linear mixed-effects models evaluated factors associated with TFV-DP/FTC-TP.

Results

Eighty-four participants (11% female, 4% transgender) predominantly receiving bictegravir/TAF/FTC (73%) were enrolled. Ninety-two percent completed week 12 or 16 (94% unboosted ART). TFV-DP for <85% (7/72), 85%–<95% (9/72), and ≥95% (56/72) cumulative adherence was 2696 (2039–4108), 3117 (2332–3339), and 3344 (2605–4293) fmol/punches. Adjusting for cumulative adherence, TFV-DP was higher with boosted ART, lower body mass index, and in non-Black participants. FTC-TP for <85% (14/77), 85%–<95% (6/77), and ≥95% (57/77) 10-day adherence was 3.52 (2.64–4.48), 4.58 (4.39–5.06), and 4.96 (4.21–6.26) pmol/punches. All participants with ≥85% cumulative and 10-day adherence had TFV-DP ≥1800 fmol/punches and FTC-TP ≥2.5 pmol/punches, respectively. Low-level viremia (HIV-1 RNA 20–199 copies/mL) occurred at 18% of visits in 39% of participants with similar TFV-DP (3177 [2494–4149] fmol/punches) compared with suppressed visits (3279 [2580–4407] fmol/punches).

Conclusions

TFV-DP ≥1800 fmol/punches and FTC-TP ≥2.5 pmol/punches represent DBS benchmarks for ≥85% adherence to unboosted TAF/FTC-based ART. Among PWH with high adherence, low-level viremia was common. Clinical Trials Registration NCT04065347.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsDried Blood Spot TestingEmtricitabineHIV InfectionsDrug MonitoringAdultFemaleHumansMaleMiddle AgedAlanineBenchmarkingOrganophosphatesTenofovir

Stichwörter der Autor:innen

adherence benchmarksdried blood spotslow-level viremiatenofovir alafenamidetenofovir diphosphate

Substanzen

AdenineAlanineAnti-HIV AgentsEmtricitabineOrganophosphatestenofovir alafenamideTenofovirtenofovir diphosphate

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • etectRx, Gainesville, Florida, USA.
  • Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Ryan P Coyle, Peter R Chai, Peter L Anderson

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Coyle, R. P., Morrow, M., Mann, S. C., Mainella, V., Ellis, S. L., Schwab, S., Coppinger, C., Barker, N., Ellison, L., Zheng, J. H., Al Zuabi, S., Alpert, P. E., Carnes, T. C., Buffkin, D. E., Chai, P. R., Bushman, L. R., Kiser, J. J., MaWhinney, S., Brooks, K. M., …, & Castillo-Mancilla, J. R. (2024). Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae212

Vancouver

Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, et al. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF). Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae212

BibTeX
@article{Coyle2024,
  author = {Coyle, Ryan P and Morrow, Mary and Mann, Sarah C and Mainella, Vincent and Ellis, Samuel L and Schwab, Stefanie and Coppinger, Corwin and Barker, Nicholas and Ellison, Lucas and Zheng, Jia-Hua and Al Zuabi, Subhi and Alpert, Pamela E and Carnes, Tony C and Buffkin, D Eric and Chai, Peter R and Bushman, Lane R and Kiser, Jennifer J and MaWhinney, Samantha and Brooks, Kristina M and Anderson, Peter L and Castillo-Mancilla, Jose R},
  title = {Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine–Based Antiretroviral Therapy (QUANTI-TAF)},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae212}
}
Kostenlos starten →